Ultragenyx Pharma (RARE) PT Lowered to $47 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts RARE Hot Sheet
Price: $16.63 +2.02%
Rating Summary:
13 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
13 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
Wedbush analyst Laura Chico lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $47.00 (from $48.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- Philip Morris (PM) PT Raised to $232 at Stifel
- UBS Downgrades Alphatec Holdings (ATEC) to Neutral
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
